The QualityStocks Daily Friday, January 6th, 2023

Today's Top 3 Investment Newsletters

The Stock Dork(SPRB) $2.4200 +93.60%

QualityStocks(MDVL) $0.5550 +80.19%

MarketBeat(ALGS) $1.3100 +32.32%

The QualityStocks Daily Stock List

Spruce Biosciences (SPRB)

MarketBeat, StreetInsider and QualityStocks reported earlier on Spruce Biosciences (SPRB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Spruce Biosciences Inc. (NASDAQ: SPRB) is a biopharmaceutical firm that is focused on the development and commercialization of new therapies for rare endocrine disorders.

The firm has its headquarters in Daly City, California and was incorporated in 2014, on November 13th. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm serves consumers in the United States.

The company’s mission is to develop meaningful therapies for patients with rare ailments which affect the hypothalamic-pituitary-adrenal pathway. It is party to a license agreement with Eli Lilly and Company, which entails the research, development and commercialization of compounds for different pharmaceutical uses. The company is committed to transforming the quality of life for patients who’ve been underserved by scientific innovation.

The enterprise’s portfolio comprises of a non-steroidal therapy dubbed tildacerfont, which has been developed to decrease steroid burden and improve disease control for patients who suffer from CAH (congenital adrenal hyperplasia). The formulation is in phase 2 clinical trials being evaluated for its effectiveness in treating children with classic congenital adrenal hyperplasia, as well as for females with polycystic ovary syndrome. It also develops CAHmelia-203, which is in phase 2b trials for adults with classic CAH with poor and good disease control.

The company recently released its third quarter financial results for 2021, with its CEO noting that it was focused on advancing its tildaverfont formulation for congenital adrenal hyperplasia and polycystic ovarian syndrome. The success and approval of this formulation will address the unmet needs of patients with these indications, as well as bring in more investments into the company.

Spruce Biosciences (SPRB), closed Friday's trading session at $2.42, up 93.6%, on 63,553,375 volume. The average volume for the last 3 months is 4.646M and the stock's 52-week low/high is $0.9547/$4.18.

Medavail Holdings (MDVL)

QualityStocks, Trades Of The Day, MarketClub Analysis and MarketBeat reported earlier on Medavail Holdings (MDVL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Medavail Holdings Inc. (NASDAQ: MDVL) (FRA: 73M0) is a tech-enabled pharmacy firm that is engaged in the provision of pharmacy services.

The firm has its headquarters in Mississauga, Canada and was incorporated in 2007, on April 11th. It serves consumers in Canada.

The company operates through the pharmacy technology segment and the retail pharmacy services segment. It sells and licenses its proprietary software and hardware to retailers, health systems and other industry consumers who would like to leverage their own pharmacy operations to bring greater service, automation and convenience to their members and patients. The company also assists patients in optimizing drug adherence, leading to better health outcomes.

The enterprise is involved in the development and commercialization of a pharmacy, kiosk, mobile application and drive-thru solution. Its primary technology and product is a prescription dispensing system which is customer-interactive and controlled by the pharmacist, dubbed MedCenter. This technology is akin to a prescription-dispensing ATM or a pharmacy in a box. The MedCenter enables live pharmacist counselling through 2-way audio-video communication. The enterprise also operates a full-service retail pharmacy known as SpotRx, which uses its automated pharmacy technology. In addition to this, it develops and commercializes advanced nutrition products that boost muscle health and performance.

The firm recently entered into a strategic arrangement with Zipdrug, which selected SpotRx as its primary partner. The move will allow SpotRx to serve consumers in the Tucson area, which will not only extend the firm’s consumer reach but also afford it more expansion opportunities. This may in turn boost the firm’s growth.

Medavail Holdings (MDVL), closed Friday's trading session at $0.555, up 80.1948%, on 4,646,206 volume. The average volume for the last 3 months is 15,194 and the stock's 52-week low/high is $0.241/$3.56.

Nogin Inc. (NOGN)

We reported earlier on Nogin Inc. (NOGN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nogin Inc. (NASDAQ: NOGN) is an e-commerce, technology platform provider in the apparel and ancillary industry’s multichannel retailing, business-to-consumer, and business-to-business domains.

The firm has its headquarters in Tustin, California and was incorporated by Geoffrey Van Haeren and Jan-Christopher Nugent. It operates as part of the software-application industry, under the technology sector. The firm serves consumers around the globe.

The enterprise’s commerce-as-a-service platform's tools provide clients with capabilities around website development, photography, content management, customer service, marketing, warehousing, and fulfillment. It optimizes the e-commerce lifecycle for such D2C brands as bebe, Brookstone, Hurley, and Kenneth Cole. Its Nogin Intelligent Commerce Platform, enterprise commerce-as-a-service (CaaS) platform includes products, such as Intelligent Commerce (site management), Smart Marketer (digital marketing and predictive analytics), Smart Ship (fulfillment and WMS) and Smart Pay; intelligent commerce architecture; and foundational elements, including its data asset, CDP and AI, and flexible API. The enterprise also develops Nogin, an enterprise software solution used by brands and retailers from various industry verticals to operate and scale their ecommerce business initiatives. It serves consumer and lifestyle brands in the fashion, consumer packaged goods, beauty, health, wellness, and other retail industries.

The company, which remains committed to expanding its footprint, recently appointed a new chief revenue officer who has decades of experience in the role. This move will not only drive sales but also develop strategic relationships to accelerate its growth. This will, in turn, generate additional revenues for the company while also creating value for its shareholders.

Nogin Inc. (NOGN), closed Friday's trading session at $0.7486, off by 4.0256%, on 15,194 volume. The average volume for the last 3 months is 43,348 and the stock's 52-week low/high is $0.4102/$11.51.

Pluri Inc. (PLUR)

We reported earlier on Pluri Inc. (PLUR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Pluri Inc. (NASDAQ: PLUR) (FRA: Y55) (TLV: PLUR) is a biotechnology firm that is focused on developing placenta-based cell therapy product candidates to help treat muscle injuries, as well as hematologic and inflammatory conditions.

The firm has its headquarters in Haifa, Israel and was incorporated in 2001, on May 11th by Doron Shorrer. Prior to its name change in July 2022, the firm was known as Pluristem Therapeutics Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The enterprise develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in phase I/II clinical trials for the treatment of steroid-refractory graft versus host disease in collaboration with Tel Aviv Sourasky Medical Center, and phase III clinical trials for muscle recovery following surgery for hip fractures. The formulation has also completed a phase II trial for the treatment of acute respiratory distress syndrome associated with the coronavirus infection and a Phase I clinical trial for incomplete recovery following bone marrow transplantation. The enterprise also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation. It is also developing a solution for the treatment of acute radiation syndrome through its collaboration with the National Institutes of Health and the U.S. Department of Defense.

The company recently announced a change in its strategy, which will involve building long-term strategic partnerships and alliances with firms that have market access. This will bring in additional revenues into the company while also driving value for its shareholders.

Pluri Inc. (PLUR), closed Friday's trading session at $1.04, up 5.0778%, on 43,348 volume. The average volume for the last 3 months is 35,576 and the stock's 52-week low/high is $0.65/$2.27.

Coeptis Therapeutics (COEP)

We reported earlier on Coeptis Therapeutics (COEP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP) is a biopharmaceutical firm focused on the development and commercialization of branded and generic pharmaceutical products and cell therapy platforms for cancer patients.

The firm has its headquarters in Wexford, Pennsylvania and was incorporated in 2017. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in the United States.

The company develops innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. It is party to a collaboration with Vici Health Sciences LLC, entailing the co-development and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. This is in addition to a collaboration with Statera BioPharma for the development and commercialization of STAT-201 for Crohn's disease. The company operates through its Coeptis Pharmaceuticals Inc. and Coeptis Therapeutics Inc. subsidiaries.

The enterprise’s product portfolio comprises of an in vitro screening tool dubbed CD38-Diagnostic, which provides the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies; and CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia.

The company recently entered into an agreement with IQVIA, a leading provider of advanced analytics, technology solutions and contract services globally. This move will not only support the development of a multi-antigen CAR T-cell technology and extend the company’s reach but also help create shareholder value.

Coeptis Therapeutics (COEP), closed Friday's trading session at $1.92, off by 1.0309%, on 35,576 volume. The average volume for the last 3 months is 708 and the stock's 52-week low/high is $1.03/$21.42.

Actelis Networks (ASNS)

MarketClub Analysis, TopPennyStockMovers, StreetInsider, StockMarketWatch, QualityStocks, Small Cap Firm, Schaeffer's, MarketBeat and Jason Bond reported earlier on Actelis Networks (ASNS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Actelis Networks Inc. (NASDAQ: ASNS) is a networking solutions firm that is focused on the development and marketing of access broadband equipment for copper and fiber networks.

The firm has its headquarters in Fremont, California and was incorporated in 1997 by Kamran Elahian, Tuvia Barlev and Yuval Baron. It operates as part of the communication equipment industry, under the technology sector. The firm serves consumers in Europe, North America, Africa, the Middle East and the Asia Pacific.

The company’s mission is to enable secure, fast, cost-effective and easy implementation of communication. Its networking solutions use a combination of newly deployed fiber infrastructure and existing copper and coaxial lines to create a highly cost-effective, secure and quick-to-deploy network.

The enterprise offers networking solutions for Internet of Things projects enabling applications in smart cities, airports, smart campuses, military bases, smart rail, smart roads and utilities. Its portfolio of hybrid fiber-copper, aggregation switches, high density Ethernet devices, advanced management software, and cyber-protection capabilities unlocks the hidden value of networks delivering connectivity for deployment. It accelerates its broadband services to businesses and residential subscribers through Broadband Accelerator (BBA), EFMplus, Dynamic Rate Boost (DRB) and Dynamic Spectral Shaping (DSS). The enterprise serves providers of telecommunication services and enterprises, as well as resellers of its products.

The firm was recently selected by Northern Ireland Railways to enable high-speed connectivity in a large-scale safety critical project. This move not only extends the firm’s reach but also opens it up to new growth and investment opportunities, which will positively influence its growth.

Actelis Networks (ASNS), closed Friday's trading session at $0.4604, off by 7.92%, on 708 volume. The average volume for the last 3 months is 87 and the stock's 52-week low/high is $0.4004/$3.94.

ProMIS Neurosciences (PMN)

QualityStocks, Streetwise Reports and PCG Advisory reported earlier on ProMIS Neurosciences (PMN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ProMIS Neurosciences Inc. (NASDAQ: PMN) (TSE: PMN) (FRA: 23JO) is a development-stage biotechnology firm that is focused on the discovery and development of precision medicine solutions for treating neurodegenerative illnesses, like multiple system atrophy, amyotrophic lateral sclerosis and Alzheimer’s disease.

The firm has headquarters in Toronto, Canada and was incorporated in 2004, on January 23th by Vigen Nazarian and Neil Cashman. Prior to its name change in July 2015, the firm was known as Amorfix Life Sciences Ltd. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in Canada.

The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. It operates through its ProMIS Neurosciences (US) Inc. (ProMIS USA) subsidiary.

The enterprise’s lead product candidates include PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. It also plans to investigate additional synucleinopathies, including Parkinson disease (PD), and dementia with Lewy bodies (DLB).

The firm, which recently announced its latest financial results, remains focused on advancing its therapeutic antibodies selective for toxic oligomers. The success and approval of its formulations will not only address the unmet medical needs of patients living with serious illnesses but also encourage more investments into the firm.

ProMIS Neurosciences (PMN), closed Friday's trading session at $4.06, even for the day, on 87 volume. The average volume for the last 3 months is 29,657 and the stock's 52-week low/high is $4.06/$9.80.

FSD Pharma Inc. (HUGE)

QualityStocks, Schaeffer's, BUYINS.NET, StockMarketWatch, MarketClub Analysis, Penny Dreamers, InvestorPlace, CFN Media Group and AwesomeStocks reported earlier on FSD Pharma Inc. (HUGE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced that key executives will be attending the 41st annual J.P. Morgan Healthcare Conference. Scheduled for Jan. 9–12, 2023, in San Francisco, California, the conference has become largest and most informative healthcare investment symposium in the industry. The event is known for gathering together global industry leaders with officials from emerging fast-growth companies along with innovative technology creators and members of the investment community. FSD Pharma director and CEO Dr. Lakshmi P. Kotra and FSD Pharma founder and president Zeeshan Saeed will be attending the conference; the two company officials will be available for in-person meetings throughout the conference.

To view the full press release, visit

About FSD Pharma Inc.

FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound FSD201, an ultramicronized palmitoyl ethylamine (“PEA”) for the treatment of inflammatory diseases. Lucid Psycheceuticals Inc. is a wholly owned subsidiary focused on the research and development of its lead compounds: Lucid-PSYCH and Lucid-MS. Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. For more information about the company, please visit

FSD Pharma Inc. (HUGE), closed Friday's trading session at $0.82, even for the day, on 29,657 volume. The average volume for the last 3 months is 16.484M and the stock's 52-week low/high is $0.6181/$1.11.

Freeport-McMoRan Inc. (FCX)

MarketClub Analysis, The Street, InvestorPlace, Schaeffer's, Kiplinger Today, SmarTrend Newsletters, StocksEarning, MarketBeat, Barchart, StreetAuthority Daily, Trades Of The Day, StreetInsider, Investopedia, TopStockAnalysts, Money Morning, Daily Trade Alert, Louis Navellier, Zacks, VectorVest, Trading Markets,, ProfitableTrading, The Growth Stock Wire, Daily Wealth, The Wealth Report, Top Pros' Top Picks, TheStockAdvisors, StreetAlerts, All about trends, The Online Investor, Wall Street Elite, Streetwise Reports, Leeb's Market Forecast, TradingMarkets, Market FN, QualityStocks, Trading Tips, Dividend Opportunities, Market Report, TheStockAdvisor, InvestmentHouse, StockTwits, Investor Guide, Investors Alley, Wealth Insider Alert, Investment House, Trading Concepts, Early Bird, Money and Markets, Options Trader Elite, INO Market Report, The Best Newsletters, InvestorGuide, Market Intelligence Center Alert, AnotherWinningTrade, Wyatt Investment Research, Investing Signal, Wealth Daily, Bourbon and Bayonets, Energy and Capital, Trade of the Week, The Motley Fool, Buttonwood Research, Darwin Investing Network, Investor Update, MarketWatch, Market Authority, Profit Confidential, Wealthpire Inc., Super Stock Investor, TradingAuthority Daily, Wall Street Daily, Cabot Wealth, Stock Research Newsletter, Street Insider, InvestorsUnderground, AllPennyStocks, CNBC Breaking News, Daily Markets, Uncommon Wisdom and FeedBlitz reported earlier on Freeport-McMoRan Inc. (FCX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Last year proved to be a mixed bag of a year for precious metals and gold, in particular. The year was characterized by a significant amount of turbulence, with Russia’s invasion of Ukraine, historic inflation, consecutive interest rate hikes by the Fed and failures within the cryptocurrency space making the global markets extremely volatile.

Gold, which has traditionally acted as a store of value during times of economic upheaval, exhibited price volatility for the majority of the year amid global inflation, the rising cost of living and high interest rates.

Despite this volatility, gold prices trended upward as the year drew to a close, finally achieving a six-month high in late December to trade at slightly more than $1,800 per troy ounce. By the end of the year, gold was down by only 1.5% while U.S. government bonds saw a loss of 10% and the S&P 500 was down by more than 19%. The upshot of gold’s performance was that investors were able to limit their portfolio losses by storing some of their assets in gold.

A cursory glance at the most popular stories that were published last year on reveals that a majority of the reports had something to do with either gold mining stocks, the precious metal itself or other hard assets.

Moves by the U.S. Federal Reserve to forestall inflation by tightening its monetary policy coupled with a strong dollar caused gold prices to drop from their peak in March 2022 until they bottomed out at $1,700 per ounce, the lowest level in two and a half years. However, the precious yellow metal rallied strong in the last three months of the year, climbing by around 10% and proving to be among the most resilient asset classes of 2022. The NYSE Arca Gold Miners Index also recorded a rise in gold mining stocks of more than 32% since the two-year low in September.

Given gold’s rally in late 2022, along with its relatively resilient performance throughout the year in the face of numerous negative market factors, experts predict that the metal will perform even better in 2023. Commodities strategist Ole Hansen predicted in his 2023 outlook that once the market realizes that inflation could stay high amid aggressive monetary policy, gold prices could climb up to $3,000 an ounce. Hansen had been predicting a monster gold rally since 2020, and he said that gold prices could even climb as high as $4,000 an ounce.

Regardless of which way the movements in the price of gold go during 2023, you can be sure that extractors such as Freeport-McMoRan Inc. (NYSE: FCX) will be keeping a keen eye on the situation and recalibrating their projections as needed.

Freeport-McMoRan Inc. (FCX), closed Friday's trading session at $42.28, up 6.1245%, on 16,483,777 volume. The average volume for the last 3 months is 231,317 and the stock's 52-week low/high is $24.80/$51.99.

Seelos Therapeutics Inc. (SEEL)

QualityStocks, MarketBeat, StockMarketWatch, MarketClub Analysis, TradersPro, Schaeffer's, BUYINS.NET, Trades Of The Day and INO Market Report reported earlier on Seelos Therapeutics Inc. (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

New research has found that one dose of psilocybin administered together with therapy significantly alleviates symptoms of depression. Psilocybin is the primary psychoactive compound found in magic mushrooms. This compound, which alters an individual’s state of consciousness when consumed, has been used for centuries in religious and spiritual rituals.

In the last few years, numerous studies on psilocybin have been conducted to determine its potential therapeutic benefits. While promising results have been observed when the substance is used in managing anxiety and depression, more studies are required to fully understand the effectiveness of psilocybin therapy.

The latest study, carried out by Robin von Rotz at the University of Zurich, was focused on finding out psilocybin’s therapeutic potential. The research involved 52 participants, all of whom had been diagnosed with major depressive disorder. Each participant was required to undergo medical screening after which they went through a pair of preparatory visits before the placebo or psilocybin dose was administered.

The researchers also asked participants whether they had used psychedelic drugs before; 16 of them admitted to having ever done so.

The scientists then used a double-blind procedure to administer the placebo or one dose of psilocybin randomly, following this up with a counseling session. The researchers administered mannitol as the placebo drug, as it was identical in weight, size, color and shape to the psilocybin pill administered.

During the trip, participants listened to music via speakers or headphones and had a trained therapist in the room with them. The therapists helped them deal with any difficult emotions they experienced, with the investigators evaluating the severity of their depression symptoms using Beck’s Depression Inventory and the Montgomery-Åsberg Depression Rating Scale.

This led to the discovery that psilocybin-assisted therapy was effective in reducing symptoms of depression. The researchers observed that in comparison to the control group, those who received one dose of psilocybin experienced a -13 point reduction in the severity of their symptoms.

In their report, they noted that this reduction persisted until two weeks after the session.

In an interview, von Rotz explained that the primary takeaway from the study was that one dose of psilocybin administered together with psychological support in major depressive disorder patients was capable of rapidly alleviating symptoms of depression. He added that despite this, more studies into modes of treatment action were needed to draw a clear conclusion.

The double-blind, placebo-controlled study’s findings were published in eClinicalMedicine.

Many more companies are conducting their own studies on psychedelics, including Seelos Therapeutics Inc. (NASDAQ: SEEL). We can look forward to more exciting revelations about psychedelic substances that have been thrust into the limelight in recent years.

Seelos Therapeutics Inc. (SEEL), closed Friday's trading session at $0.7849, off by 3.0988%, on 231,317 volume. The average volume for the last 3 months is 6.943M and the stock's 52-week low/high is $0.4803/$1.58.

Nikola Corporation (NKLA)

Green Car Stocks, InvestorPlace, Schaeffer's, MarketClub Analysis, StocksEarning, QualityStocks, The Street, MarketBeat, Kiplinger Today, Trades Of The Day, StreetInsider, Daily Trade Alert, The Online Investor, Early Bird, Zacks, Cabot Wealth, Louis Navellier, Wealth Insider Alert, CNBC Breaking News, MarketTamer, Outsider Club, AllPennyStocks, StockMarketWatch, Daily Profit and Investopedia reported earlier on Nikola Corporation (NKLA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

In December, BYD proved Warren Buffett’s Berkshire Hathaway’s confidence in the company was not misplaced by recording a huge number of EV sales and solidifying its spot as the leading seller of non-fossil-powered vehicles in the world.

BYD, a car manufacturer based in Shenzhen, China, reported that sales of its all-electric vehicles increased 4% from November to December. With the majority of the sales being in China, BYD saw its sales triple to 1.86 million cars overall last year.

Since March 2022, BYD, which began as a battery manufacturer, has seen its sales increase monthly, setting new records in 10 straight months and dethroning Tesla in the second quarter. The final quarter of 2022 saw Tesla ship 405,278 units globally, missing its quarterly estimate by 6%. Despite an increase in total global deliveries last year to 1.31 million vehicles, accounting for 40% of total sales, Tesla still trails BYD in sales by 29%.

According to Eric Han, the senior manager of Suolei, a Shanghai-based advisory firm, the slowing Chinese economy brought on by the pandemic has resulted in consumers turning away from imported models of foreign brands such as Tesla in favor of less expensive locally produced EVs. This trend benefits BYD since the middle-class consumers in China are favorable toward the mass-produced cars by the company because they perceive the vehicles as good value for their money.

The majority of BYD vehicles range in price from 100,000 to 200,000 yuan ($14,548–$29,096), which is less expensive than Tesla and other competitors, including Xpeng and Nio, whose technologically advanced vehicles are priced above 300,000 yuan ($43,645) per vehicle. Customers in white-collar jobs prefer BYD vehicles because they are inexpensive and allow them to save, said Tian Maowei, sales manager of Yiyou, a Shanghai-based auto service. He added that BYD and plug-in hybrid vehicles are easily sold in their home markets since they are equipped with powerful batteries thought to be just like those being used by the high-priced carmakers. Chinese drivers as well as Tesla have attested to the quality of BYD’s blade lithium batteries.

Even though the China Passenger Car Association predicts that the increase in China’s electric vehicle deliveries might slow down to 30% in 2023 because of the elimination of cash subsidies,  China remains the world’s largest market for electric vehicles. Three out of five new vehicles on Chinese roads are expected to be battery powered by the year 2025, a UBS report showed.

Tesla continues to dominate the mainland market for premium electric vehicles.

The fortunes of these two titans could provide some insights into how startups such as Nikola Corporation (NASDAQ: NKLA) can position themselves and the different models they develop for the market.

Nikola Corporation (NKLA), closed Friday's trading session at $2.13, off by 0.46729%, on 6,943,214 volume. The average volume for the last 3 months is 498,500 and the stock's 52-week low/high is $2.01/$11.87.

Bit Digital Inc. (BTBT)

QualityStocks, MarketClub Analysis, StocksEarning, Schaeffer's, TradersPro, StockEarnings, MarketBeat, InvestorPlace and Daily Trade Alert reported earlier on Bit Digital Inc. (BTBT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

While future predictions should be made with caution, Euronews Next has highlighted several major tech trends that will be prevalent in 2023. The metaverse bubble hype appears to have given way to AI, while cryptocurrency prices continue to fall amid numerous controversies and economic pressure and the tech sector has been severely impacted by mass job cuts.

Crypto prices

Last year’s crypto prices were heavily impacted by difficult economic conditions. For starters, the third-largest crypto exchange, FTX, which was headed by Sam Bankman-Fried, spectacularly collapsed, shocking the sector as a whole. It occurred at a time when the total value of the cryptocurrency market had fallen by more than $1.4 trillion in the year due to numerous crashes, including the Terra Luna saga.

According to Samantha Yap, founder and president of YAP Global, a global PR and communication services consultancy specializing in blockchain and decentralized finance, it has been a trying year for the cryptocurrency and Web3 industries because markets have experienced turbulence because of the increase and collapse of Terra Luna and FTX.

Yap did, however, add that the development of multichain ecosystems over the previous year has eliminated the need for users to switch networks when conducting transactions across multiple chains at once.

European Union technology regulation

This year, government regulations, particularly those concerning cryptocurrencies, are anticipated to have a major impact on the industry.

The EU regulation known as the “Trading in Digital Currencies (MiCA) Regulation,” which governs the transfer of digital assets among member states, is scheduled to go into effect in the early months of 2023. The bill aims to support the evolution of the crypto asset market while simultaneously protecting investors and preserving financial stability.

Additionally, the Digital Services Act, which undoubtedly takes effect on Sept. 1, 2023, is something that online platforms should be prepared for, according to Thierry Breton, head of internal markets for the European Union.

The purpose of the DSA legislation, which primarily targets social media companies, is to combat online hate speech and misinformation, safeguard children and stop consumer fraud.


The creation of ChatGPT, a powerful AI chatbot that self censors and generates text on demand, is one of the most significant developments in artificial intelligence. The application, created by the OpenAI Foundation, was released as a prototype on Nov. 30, 2022, and quickly gained popularity for its thorough and intelligent responses in a wide range of subject areas.

As a result of its ability to quickly sift through vast amounts of data and make many business decisions cheaper, AI is expected to have an impact on every industry in the coming years.

The shaky metaverse

There was a lot of anticipation surrounding the metaverse in 2020 after Mark Zuckerberg, Meta CEO, revealed his significant bet on the VR-based industry, which unfortunately didn’t go as planned.

The pricey shift in emphasis has angered Meta’s shareholders, who have seen the company’s stock declined by more than 65% this year.

Economic difficulties in the tech sector

Not only Meta but also other technology behemoths such as Twitter, Amazon and Lyft have seen layoffs.

According to Chowdhury, the U.S. technology sector in particular started off hiring way too quickly, and as a result, development and profitability have plateaued, leading to employment losses. However, this can present a chance for specialized or small-sized IT companies to hire employees from the industry’s titans.

It remains to be seen how market players such as Bit Digital Inc. (NASDAQ: BTBT) will respond to those trends this year.

Bit Digital Inc. (BTBT), closed Friday's trading session at $0.732, off by 6.1538%, on 498,500 volume. The average volume for the last 3 months is 3,600 and the stock's 52-week low/high is $0.5301/$6.23.

The QualityStocks Company Corner

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF).

Methane, a potent greenhouse gas, accounts for over 30% of globalwarming dating back to pre-industrial times

Despite its connotations as a relatively clean fossil fuel, naturalgas is 70-90% made up of methane

A key source of greenhouse emissions in recent year has been theleakage of methane from natural gas fracking operations

Renewable Natural Gas presents a carbon neutral alternative tonatural gas, with production increasing by over 20% YoY in both,the United States and Canada over the past year

EverGen Infrastructure Corp. has been at the forefront of thedevelopment of North America’s RNG production capacity; by early2023, the company targets over 230 gigajoules per day of RNGproduction capacity

Methane, a potent greenhouse gas and major contributor to globalwarming, has historically borne an association with cow burps andwetlands ( Over 80 times more potent than carbon dioxide, methane has beenfound to account for approximately 30 percent of global warmingsince pre-industrial times and is currently proliferating fasterthan at any time since record keeping first began in the 1980s ( In comparison, natural gas has been hailed as the potential‘bridge’ fuel towards a greener future, with consumers pointingtowards the relatively lower carbon emissions generated through theuse of natural gas relative to the likes of crude oil and thermalcoal. Nonetheless, and despite its greener connotations andperception as a largely benign fossil fuel, natural gas is composedof 70-90 percent methane (, an oft forgotten statistic by natural gas advocates.British-Columbia based natural gas operator, EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF) has been at the forefront of renewable natural gas production inNorth America, a process which has looked to harness methane as akey input with the eventual goal of manufacturing a ‘cleaner’alternative to conventional fossil fuels. Unlike regular naturalgas, RNG is not obtained from fossil resources; rather, itconstitutes a carbon-neutral or even, carbon-negative fuel.Nevertheless, and despite its potential to contribute towardsglobal carbon neutrality goals, RNG production has historicallybeen limited given its relatively high cost and limitedavailability.

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQX: EVGIF), closed Friday's trading session at $1.64, up 4.7923%, on 3,600 volume. The average volume for the last 3 months is 300 and the stock's 52-week low/high is $1.365/$4.00.

Recent News

Correlate Infrastructure Partners Inc. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).

Correlate Infrastructure Partners (OTCQB: CIPI), a tech-enabled development, finance and fulfillment platform fordistributed energy solutions across North America, is helping toadvance progress on the greenhouse gas reduction front. “Thecompany is making it easier and cost effective for those in thecommercial real estate industry to acquire the necessary solutionsfor solar, cogeneration, energy storage, and electric vehicleinfrastructure, as well as driving intelligent efficiency retrofitsfor community-scale applications… Correlate provides proprietaryanalytics and advisement for companies seeking to reduce the carbonfootprint of their buildings before helping clients navigate thetricky journey toward managing and financing infrastructureimprovements for a better and more affordable ESG [environmental,social and governance] outcome,” a recent article reads. “CorrelateInfrastructure Partners is making energy management and procurementtransparent and cost-effective as we digitize the process that hasbeen archaic for way too long,” CEO Todd Michaels is quoted assaying. “We are excited to be at the forefront of an industry thatis at an inflection point, and we are eager to begin working tochange the way commercial real estate owners optimize energyassets.”

To view the full article, visit

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.

The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.

CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.

The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.

CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.


Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.

Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.

Market Outlook

CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.

Management Team

CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.

Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.

Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Friday's trading session at $1.08, up 1.8868%, on 300 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.00/$.

Recent News

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

Similar to humans, animals such as dogs have unique behaviors theyexhibit from time to time. While most quirks are adorable, teethchattering may be caused by severe underlying issues. To help you understand why your dog’s teeth are chattering, belowwe look at reasons why that may happen.


Your dog is cold


Your dog’s teeth may chatter when it is in a cold environment. This shows that the animal is not comfortable with the currenttemperature, so if it is outside, you should bring your pet inside.

Alternatively, if an animal’s teeth are chattering while inside thehouse, then the house may be chilly. Consider covering your dogwith a blanket or a pet sweater if one is available. If you want,you could even purchase a heated bed to ensure your furry friend isextra comfortable at home. Just like people, dogs may experiencetrembles caused by nervousness. Most dogs may even experience teethchattering and full-body shakes when they are nervous or scared.This is a normal stress response, so there’s nothing to be worriedabout. For dogs whose seizures are due to less benign causes,entities such as India Globalization Capital Inc. (NYSE American: IGC) are developing next-gen therapeutics from cannabis compounds sothat people’s furry companions enjoy symptomatic relief withouttriggering serious side effects

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule ( As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products ( such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand ( that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.


IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.


The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Friday's trading session at $0.324, up 4.5836%, on 605,114 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2785/$1.16.

Recent News

MetAlert Inc. (OTC: MLRT)

The QualityStocks Daily Newsletter would like to spotlight MetAlert Inc. (OTC: MLRT).

The CDC estimates that by 2060, over 14 million Americans may bediagnosed with Alzheimer’s, up from the current 6.5 million

In a surprising study, presented at the 2022 Alzheimer’sAssociation International Conference, it was noted that this risecould be largely attributed to people’s intake of ultra-processedfoods, which was linked to a higher risk of dementia

Of the 10,000 participants who took part in the study, it was notedthat those who ate the most ultra-processed foods had a 28% fasterrate of global cognitive decline, and a 25% faster rate ofexecutive function decline compared to those who ate the leastamount of overly processed food

MetAlert is pushing for lifestyle and dietary changes while helpingto sensitize people on the risks associated with the consumption ofultra-processed foods

Even as it continues to design, develop, manufacture, distributeand sell products and services in the GPS/BLE wearable technologyspace, MetAlert is strongly pushing for healthier dietary andlifestyle alternatives guaranteed to reduce the risk of cognitivedecline

MetAlert (OTC: MLRT), a developer of personal protective medical equipment and suppliesand a pioneer in wearable GPS, human, and asset tracking systems,has, since its inception, shown a commitment to those afflictedwith Alzheimer’s, dementia, and autism (“ADA”). This commitment hasgone beyond developing location-sensitive health monitoringdevices, particularly with the Centers for Disease Control (“CDC”)estimating that by 2060 over 14 million Americans may be diagnosedwith Alzheimer’s, up from the current 6.5 million ( (OTC: MLRT), a pioneer in location-sensitive health monitoring devices andwearable technology products for remote patient monitoring, wasfeatured in two recent reports published by Ludlow Research. In both reports, Ludlow issued an upgrade research opinion onMetAlert with a valuation target of $1.00 to $1.25 per share. Theupgrades were based on various factors, including MetAlert’sagreement with a major IoT connectivity company out of Germany, itsexpansion of medical devices for the aging and autism markets,ramp-up in SmartSole unit production to fulfill backorders, as wellas elimination of toxic debt. “In recent months, MetAlertextinguished all of their toxic convertible notes from theirbalance sheet, which should now provide increased stability totheir public float. The influx of new chips in Q4 2022 shouldsignificantly increase production of SmartSole units in early 2023.This ramp-up in production should help fulfill backorders currentlyin place and increase revenues in the coming months,” reads thelatest update. “The elimination of toxic debt, improved guidance totheir NFC operations, and launch of new medical devices gearedtowards the geriatric and autism health care markets now places thecompany in a much healthier position going forward into 2023.” Toview the full reports, visit and

MetAlert Inc. (OTC: MLRT) is a pioneer in location sensitive health monitoring devices (estimated $47 billion industry in 2021) and wearable technology products (industry forecast to reach $174 billion by 2030).

With over 20 years of experience and an extensive patent portfolio (30+), MetAlert is a leader for consumers/patients afflicted with Alzheimer’s, dementia, and autism (ADA). This market represents approximately 2.9% of the world’s population (approximately 34 million people in 24 developed countries). Due to specific behaviors (problems with memory, adversity to wearing unknown items, etc.) of consumers/patients in this market segment, traditional products, such as an iPhone or Fitbit, are not a practical solution. This has created a significant market with very few competitors for MetAlert.

MetAlert and its subsidiaries are engaged in designing, developing, manufacturing, distributing, and selling products and services in GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring. The company offers a global end-to-end hardware, software, and connectivity solution, in addition to developing two-way tracking technologies, which seamlessly integrate with consumer products and enterprise applications.

Using its award-winning, patented GPS SmartSole® as a hub for collecting and transmitting data to the cloud in real-time, MetAlert is expanding its value proposition to consumers and increasing its revenue per user (RPU) while creating the largest database of health statistics for ADA consumers/patients. MetAlert generates revenue from product sales, recurring subscriptions, intellectual property (IP) licensing, and professional services. The company has international distributors servicing customers in over 35 countries and is an approved U.S. military government contractor. Its customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers.

The company is headquartered in Los Angeles, California, with a sales office in London, England, and distributors across the globe.


  • GPS SmartSoles® HUB (launched Q4 2022) is a GPS/BLE-equipped insole that allows remote monitoring, data collection, and encrypted data transmission to the cloud.
    • Telehealth (available Q4 2022) allows access remotely to doctors and other health professionals on an as-needed basis. This service will also function as the prescribing doctor once Medicare reimbursement codes are established.
    • Concierge (available Q4 2022) provides 24/7/365 enhanced emergency response that coordinates with all relevant parties to quickly detect false alarms and escalate response as needed.
    • Bluetooth Enabled Devices (available Q1 2023) include third-party devices that collect vitals and other health data and connect with the GPS Smartsoles® HUB.
    • Artificial Intelligence (available Q1 2023) software will evaluate the Teradata of health information identifying trends and respond to preestablished alert thresholds.
  • Take-Along Tracker is a small GPS tracking device – less than three inches long – that works with 4G cellular service and will have the same “HUB” functionality as the GPS Smartsoles®. This versatile and affordable mini tracker boasts super long battery life, with up to 14 days of operation per charge.
  • RoomMate™ is a wall-mounted alert system that detects and alerts caregivers about patient behavior that could lead to falls and injuries. The system features 3D infrared and wall-mounted sensors, eliminating the need for any other physical installation or wearables. RoomMate™ offers patient privacy by design. Images are not stored, but all actions are logged. It’s a unique solution for looking after patients without intruding on their personal space.

Market Outlook

According to Grand View Research (Patient Monitoring Devices Market Size & Share Report, 2030), the global patient monitoring devices market size was valued at $47.0 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.8% from 2022 to 2030. The expansion of the industry can be attributed to the rise in demand for monitoring devices used to measure, distribute, record, and display a variety of biometric data, including blood pressure, temperature, and blood oxygen saturation level.

The growing number of chronic disorders, such as diabetes, stroke, and kidney disease, are driving the demand for patient monitoring devices. For instance, according to the World Health Organization (WHO), about 422 million people globally have diabetes. Likewise, the number of asthma and chronic obstructive pulmonary disease patients (COPD) is increasing rapidly.

According to the WHO, around 235 million people suffer from asthma. As a result, peak flow meters, which are used to gauge respiration rate, are increasingly used. The market for patient monitoring devices is driven by the simplicity with which it is handled, transported, and remotely accessible. Major market players are engaging in a variety of tactics to expand the industry, including partnerships, cooperation, innovation, launches, and mergers.

During the COVID-19 outbreak, social segregation and quarantining procedures were put into place worldwide. Many people avoided regular hospital visits as a result. Many people now need routine home temperature and oxygen level monitoring to maintain track of their health, thereby demanding monitoring devices at home.

Various government programs are supporting the pandemic outbreak. The FDA has granted Emergency Use Authorizations (EUAs) for a few wearables and patient monitoring devices to improve access to medicines, monitor patients more closely, and lessen the risk of SARS-CoV-2 exposure to medical professionals during the COVID-19 pandemic.

The growing popularity of wearable and remote patient monitoring devices is another factor fueling the market’s expansion. By fusing clinical symptomology with vital indicators, wearable technology helps in the diagnosis of many chronic diseases. Thus, there has been a dramatic rise in the usage of wearable technology to combat COVID-19.

The wearable medical device market is anticipated to reach $174.48 Billion by 2030, expanding at a 27.1% CAGR during the forecast period (2022-2030), according to Market Research Future.

MetAlert identifies the total addressable market for its wearable patient monitoring tech for those with Alzheimer’s, dementia, and autism at more than 34 million potential patients in North America, Europe, South Africa, and Asia.

Management Team

Patrick E. Bertagna is Founder, CEO and Chairman at MetAlert. He began his career in apparel sales in 1983 and was promoted to national sales manager within two years. In 1986, he founded his first company importing apparel from Europe and selling to U.S. retailers from JCPenney to Neiman Marcus. He has founded several technology and apparel companies, including MetAlert in 2002, which he took public in 2008. He attended Cal State University Northridge with a business major and a psychology minor.

Louis Rosenbaum is COO of MetAlert. He co-founded Global Trek Xploration and was an initial investor in MetAlert. He has successfully started companies in multiple industries, including apparel, environmental services, and the music industry, achieving annual revenues in the multi-millions of dollars. He previously was president of Elements, a women’s apparel company, and of Advanced Environmental Services.

Alex McKean is CFO at MetAlert. He is also the CFO of Encore Brands Inc., a position he has held since 2009. He has held positions as Controller and VP of Finance at 24:7 Film and, Director of FP&A/SVP at Franchise Mortgage Acceptance Company, Corporate Accounting Manager/Treasurer of Polygram Filmed Entertainment and Assistant Treasurer/Controller for State Street Bank. He holds an International MBA from Thunderbird School of Global Management and undergraduate degrees in business and political science from Trinity University.

MetAlert Inc. (OTC: MLRT), closed Friday's trading session at $0.29, up 11.5385%, on 6,871 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.06/$1.00.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

International cannabis operator Flora Growth Corp. is rapidlyexpanding its global footprint and Colombia-based internationalsupply chain thanks to strategic acquisitions during the pastseveral months

Flora’s most recent acquisition was concluded just before Christmason finalization of an agreement with multi-national operatorFranchise Global Health Inc. that strengthens Flora’s position inEurope

Franchise Global Health (“FGH”) serves 1,200 pharmacies in Germany,which the companies regard as the doorway to the rest of Europe,and it also has a footprint in Portugal and Denmark, while FloraGrowth has completed exports to Switzerland and the Czech Republic

Flora reported a 604 percent YOY increase in revenues for the firsthalf of the year and recently added an increase of 414 percent YOYfor the Q3 period

Cannabis cultivator and global distributor Flora Growth (NASDAQ: FLGC) is entering the new year with its latest acquisition completed,opening the way for accelerated expansion into Europe’smarketplace.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.


Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Friday's trading session at $0.255, up 2.657%, on 606,148 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.21/$2.38.

Recent News

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F)

The QualityStocks Daily Newsletter would like to spotlight Hillcrest Energy Technologies Ltd. (OTCQB: HLRTF).

Hillcrest (CSE: HEAT) (OTCQB: HLRTF), a company focused on developing transformative power conversiontechnologies, recently completed its 800-volt, 250-kilowatt ZeroVoltage Switching (“ZVS”) traction inverter commercial prototype,advancing from a 10-kilowatt technical proof of concept in just oneyear. “Hillcrest’s ZVS or soft switching capabilities will seek toovercome challenges habitually found in hard-switched wide-bandgapdevices such as silicon carbide (‘SiC’) traction inverters. Throughthe material elimination of switching losses, Hillcrest’s invertertechnology has been shown to reduce the thermal management neededacross the entire powertrain system. This, in turn, can result insubstantial savings in the manufacturing process, reducing systemcomplexity and improving system reliability by reducing stressplaced upon power devices,” reads a recent article. “We’vevalidated our core technology and will continue working withHercules Electric Mobility and a Tier 1 automotive supplier, ourpreviously announced co-development partners, on integrating ourZVS traction inverter into their specific powertrain applications,”Hillcrest CTO Ari Berger is quoted as saying. “Implementing ourtechnology in these systems, expected to occur by Q2 2023, willmark another important milestone by transitioning the technologyout of our lab and into real-world demonstrations of the HillcrestZVS inverter in commercial applications.”

To view the full article, visit

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) is a clean technology company based in Vancouver, British Columbia, engaged in developing high-value, high-performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable energy systems.

From concept to commercialization, Hillcrest invests in the development of energy solutions that power a more sustainable and electrified future. Hillcrest power inverter technology helps produce efficiencies in electrification and maximize the performance of electric systems, including electric vehicles (EV), motors and generators.

The company offers a flexible, single-inverter architecture that can be applied at nearly every stage of the electrification ecosystem, from renewable energy generation through the charging and operation of an EV, to provide full-cycle efficiency and performance improvements.

As momentum to electrify and decarbonize energy systems accelerates, Hillcrest believes the power inverter is increasingly emerging as a key component. While system cohorts such as battery packs, PV panels and electric motors are often in the spotlight, the inverter holds the key to unlocking efficiency and performance improvements.

Hillcrest power inverter technology is:

  • REVOLUTIONARY: high-efficiency inverter technology has the potential to revolutionize how motors respond and how efficiency is gained.
  • AGILE: able to deliver and deploy high-efficiency inverter solutions purpose-designed to meet specific customer needs.
  • INNOVATIVE: technology-forward, clean-energy experts who are focused on advancing and optimizing efficient alternative energy use across all electric vehicle and charging platforms.
  • A MARKET LEADER: a next-generation technology provider to the automotive industry’s top suppliers and manufacturers.

Technology & Applications

Hillcrest’s first application for its inverter technology – a 250 kW|800V Hillcrest SiC high efficiency traction inverter – is focused on the growing EV market. Hillcrest technology eliminates traditional design trade-offs faced across the power industry – deploying higher switching frequencies has historically meant a greater increase in losses, lower system efficiency and higher heat. Through a combination of hardware and software expertise, Hillcrest enables power applications to leverage higher switching frequencies AND

  • Realize improved power system performance and reliability
  • Operate at higher power levels without compromising efficiency

The expected benefits of Hillcrest’s traction inverter have been confirmed via testing and shared in a technical white paper, published in April 2022, that confirmed the following results:

  • Significant efficiency gains – 99%-plus inverter efficiency
  • Increased power density targeting 50kW/L+
  • Significantly increased motor efficiency
  • Lower stress on mechanical and electrical parts, enhancing reliability
  • Improved thermal management

Hillcrest has also filed a patent for an enhanced powertrain solution that offers the potential to simplify EV charging and redefine how the industry envisions charging infrastructure. The company believes the most exciting benefit of the enhanced powertrain solution is the ability to eliminate the onboard charger and booster from an EV, as well as faster, anywhere charging including direct DC, wireless, and bidirectional charging across current and future power levels. Hillcrest sees this as a true EV charging game changer.

The company’s technology applies to nearly every clean energy industry segment:

  • Wind power – an inverter is deployed at a wind turbine generator to convert the AC output, with at least one additional inverter used to deliver the power to the grid/battery.
  • Solar power – an inverter is used to convert the DC output from the photovoltaic panels into the AC power that flows to the grid/battery/home.
  • Energy storage – an inverter is deployed to convert the DC output from the storage system or batteries to the AC power that flows to the grid/home/EV.
  • EV fast chargers – an inverter converts the AC input from the grid/storage system to the DC output needed to charge an EV’s battery.

Market Outlook

According to an April 2022 market analysis by Vantage Market Research (VMR), the global power inverter market is expected to reach a value of $95 billion by 2028, driven by increasing demand for EVs, energy generating wind turbines and solar-powered photovoltaic systems. That jump is forecast from an estimated $70.5 billion market value in 2021 and represents a compound annual growth rate of more than 5%.

According to the VMR report, many governments in countries around the world are supporting alternative options for efficient and nonpolluting energy generation. This has boosted demand for wind energy and solar energy systems. Hillcrest is aiming to capture a share of this future market growth across nearly every segment of the clean energy industry.

Management Team

Don Currie is the founding CEO of Hillcrest Energy Technologies. He has led the company’s successful transition from fossil fuels into clean energy technologies. Earlier in his career, he held various senior level positions, including director, officer and vice president of corporate communications with Enhanced Oil Resources Inc., an oil and gas exploration and production company based in Houston. Prior to that, he worked in other private and public ventures spanning the mining, gaming and technology sectors.

Jamie L. Hogue is the COO of Hillcrest. She brings more than two decades of progressive policy leadership, economic analysis and organizational development experience to Hillcrest. She builds collaborative processes and solutions that drive growing organizations toward a more resilient future. She previously served as the director of operations for Arizona State University’s Ten Across initiative – a compelling observatory positioned on the front lines of economic, social and climate change. She earned a master’s degree in public administration and a bachelor’s degree in economics from Arizona State University.

Ari Berger is Chief Technology Officer at Hillcrest. He brings over a decade of commercial experience with a track record of deploying new electrification technologies and go-to-market strategies. In 2015, he founded NIG Systems Ltd. in Israel, which specializes in custom high performance control systems design. Prior to this, he previously worked for Bental Industries, a leading motor manufacturer. He holds a master’s degree in system control engineering from the Technion – Israel Institute of Technology.

Raj Clair is CFO at Hillcrest. She is a CPA who began her career at Deloitte and has served in advanced finance positions in the energy and resources sector. She has been responsible for reporting, audits and internal controls, as well as working on budgeting and forecasting. She has worked with various publicly listed companies, including SEC registrants, and has both Canadian and U.S. experience. She holds a bachelor’s degree in accounting from Simon Fraser University.

Hillcrest Energy Technologies Ltd. (NASDAQ: HLRTF), closed Friday's trading session at $0.0785, up 8.2759%, on 1,500 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0682/$0.1512.

Recent News

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF)

The QualityStocks Daily Newsletter would like to spotlight Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) .

Reklaim (TSX.V: MYID) (OTCQB: MYIDF), a leader in privacy-compliant data, today announced itscollaboration with Snowflake, the Data Cloud company, to offer twocompliant data sets on Snowflake Marketplace. These include a dataset of individual consumers who have explicitly opted-in to sharingtheir sensitive personal data (“SPI”) for marketing purposes, aswell as a do-not-sell data set of consumers who have specificallyopted out of having their data sold. “With the enforcement periodof CCPA beginning in January of 2023, offering distinct consumerconsent for SPI data and do-not-sell signals to companies lookingto ensure their data remains compliant is a gap in the U.S. datamarket,” said Neil Sweeney, CEO of Reklaim. “Snowflake’s leadershipin the technology space makes offering these additional privacytools to customers on Snowflake the obvious choice.” To view thefull press release, visit

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) offers a privacy-compliant identity ecosystem both online ( and via a mobile app on iOS and Android in the U.S and Canada. Reklaim believes that consumers own their data and, consequently, have the right to access their online data and choose how it is used, whether for compensation or privacy. Reklaim gives consumers visibility regarding how their data is collected and compensates them for its use, all while also providing advertisers and brands with a source of data compliant with emerging privacy regulations.

The company is driven by the evolution of privacy and how it impacts consumers and companies. Reklaim sells compliant, zero-party data to Fortune 500 brands, platforms, and data companies so that they can offset the risk of non-compliance. ‘Zero-party data’ is data that a consumer proactively and intentionally shares with an organization. This contrasts with ‘third-party data,’ which organizations have collected unbeknownst to consumers for more than 20 years. Zero-party data is the most valuable data in the US$200B data market, as it provides organizations with explicit consumer opt-in vs. through an intermediary such as a data broker.

Reklaim empowers consumers to take back control of their data. The company allows consumers to visit the platform, confirm their identity, and uncover their data that has been collected and sold for years without their explicit consent. Consumers can add, edit or delete data that is associated with their profile and choose which pieces of data they would be willing to share for weekly compensation. Reklaim is the only company in the world today providing consumers with both access to their data that is circulating in the market and a guaranteed weekly paycheck. Alternatively, for users who do not want to sell their data, users can choose to protect their data and subscribe to a suite of subscription-based (SaaS) privacy tools that obfuscate the location of their device when browsing on a mobile phone and alert them when a third-party source has leaked their data or passwords.

Reklaim was founded in 2018 and is based in New York, with offices in Toronto.

Business Model

Reklaim’s primary revenue-generating operations stem from selling consented consumer data to companies and resellers that need data that is compliant with all applicable consumer privacy laws and regulations, including the California Consumer Privacy Act (CCPA). Major Fortune 500 customers and enterprise data platforms have validated Reklaim’s zero-party data and have added this data to their marketplaces and decision-making. Reklaim has sales across three core verticals: brands and agencies that buy advertising, platforms that sell data to Fortune 500 clients, and companies whose primary business is selling data to business customers.

  • Companies & Agencies that Buy Advertising – These customers use Reklaim’s compliant data to inform their media decisions in social, connected television, programmatic and other verticals. Sales cycles are short at about 30 days. Reklaim customers in this segment are Microsoft, Amgen, Bayer, UPS, and Hasbro, to name a few.
  • Platforms that Sell Data – Reklaim has integrated its zero-party data into 15 of the largest enterprise data platforms in the world. These platforms act as the ‘grocery stores’ of data, where the Fortune 500 come to make their data purchases. Reklaim’s data has been validated and added to these platforms, providing ubiquitous distribution of Reklaim data across the data ecosystem. Due to data quality verification and technical requirements, sales cycles are typically longer, about 60-90 days. Customers include LiveRamp, Transunion, Google, The Trade Desk, Lotame, and T-Mobile.
  • Data Companies that Sell Data – These customers need to purchase compliant data to continue offering data to their clients. Sales cycles often last 90-120 days, but these contracts are typically annual, have the highest value, and auto-renew. An example is Nielsen, the television measurement company.

Market Outlook

The data industry, valued at $245 billion in the U.S. and more than $400 billion globally, is being disrupted, and Reklaim is positioned to benefit from the destructive shift.

The disruption is driven by two factors: (1) technology is reducing access to core data that the industry has become dependent upon, and (2) government intervention is emerging through laws and regulations intended to protect consumer data privacy.

Over the past 20 years, the data industry has harvested and exploited consumer data without consumers’ express consent. However, the legal and regulatory environment surrounding consumer data acquisition is rapidly evolving, placing the consumer at the center of emerging privacy policies.

The European Union’s General Data Protection Regulation (GDPR) was rolled out in 2019, followed shortly by the CCPA and the California Privacy Rights Act. More recently, the Canadian Privacy Protection Act, Brazil’s General Data Protection Law, India’s Information Technology Act, and South Africa’s Protection of Personal Information have continued the trend. As a result, industries and companies currently relying on unconsented consumer data will experience a regulation-driven disruptive migration, forcing them sooner rather than later to use only fully consented data sources. This consumer data environment is driving companies to Reklaim to replace their current data providers.

While privacy policies continue to iterate to include the consumer, Big Tech, namely Apple and Google, are increasingly removing data from the market that brands and companies have relied on. Apple’s introduction of Advanced Ad Tracing (ATT) has impacted companies’ ability to track consumer behavior across applications. Facebook, in Q4 2021, was forced to accept a US$10B write down on revenue projections due to this change and is expecting a similar US$10B right down again in 2022.

Google is making similar changes, the most significant being the removal of the third-party cookie from its Chrome browser, which has a 65% market share. This third-party cookie is responsible for the tracking that websites use to monetize by tracking consumers. The removal of the Chrome cookie will put the 1.8 billion websites operating in the open web today under pressure to find a solution to replace the 65% loss in revenue.

Management Team

Neil Sweeney is Chairman and CEO of Reklaim. He has more than 20 years in the industry, with an established reputation for visionary entrepreneurship and an ability to develop technologies. Technologies Sweeney created are used by Fortune 500 brands like Coca-Cola, Lowe’s, Walmart, General Motors, Unilever, and Mondelez. They are the core component of top media demand-side platforms, including Adelphic, The Trade Desk, AppNexus, MediaMath, and Triton Media. He is a two-time finalist for Ernst & Young’s ‘Entrepreneur of the Year’ and received Deloitte’s ‘Fast 50’ award for three consecutive years for the growth of organizations he created.

Ira Levy is CFO at Reklaim. He has over 15 years of experience in a wide range of high-growth, early-stage public and private companies. Most recently, he held the roles of Corporate Controller at VIVO Cannabis Inc. (TSX: VIVO) and Senior VP/Head of Finance for start-up Honest Inc. (d/b/a Province Brands of Canada). He has also acted as an advisor for startup AI companies through the Creative Destruction Lab Program. He received his MBA in Accounting and Finance from the Schulich School of Business at York University and is a Chartered Professional Accountant.

Jake Phillips is Chief Technical Officer at Reklaim. He is a proven technology leader who excels at bridging the gap between innovation and business in dynamic environments. He has gained a breadth of industry knowledge across telco/cable, banking, and client services. His professional experience spans enterprise integration, mobility, big data, cloud operations, and data security.

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF), closed Friday's trading session at $0.023, up 14.4279%, on 120,003 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0155/$0.2389.

Recent News

REZYFi, Inc.

The QualityStocks Daily Newsletter would like to spotlight REZYFi, Inc.

Connecticut Governor Ned Lamont recently declared that the statehas expunged roughly 43,000 convictions for marijuana-related offenses. The state government was given theauthority to promote widespread cannabis clemency under legislation that Governor Lamont (D) signed in 2021, and it has since handled42,964 cases. This number was reached approximately a week beforethe start of the state’s initial legal adult-use marijuana sales.Lamont noted that the state was one step closer to winning thebattle on drugs and allowing residents a fair shot to realize theirambitions. The governor’s office has also noted that undera distinct reform bill that was passed, individuals with a widervariety of minor crimes on their files would be able to requestcourts seal their records. A White House spokesman praised Lamontfor the new marijuana amnesty announcement and noted that it isconsistent with President Joe Biden’s October decision to pardonthousands of people who had been found guilty of federalmarijuana-related offenses. The forward march of cannabislegalization around the United States opens up some potentialmarkets that specialist companies such as REZYFi Inc. can tap as they expand their reach within the industry.

REZYFi, Inc. is a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses. Its target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects.

Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent and servicing operation. REZYFi is currently licensed in 34 U.S. states, with plans to expand to all remaining states later this year.

REZYFi is positioned as one of first cannabis mortgage bankers in the U.S., while most traditional lenders are still reticent to serve the state-licensed cannabis industry.


REZYFi Lending

REZYFi Lending leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans and adjustable-rate mortgages.

Looking ahead, the company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the planned launch of a high-margin cannabis division later this year.

ResMac Inc.

ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

Through its ResMac subsidiary, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage servicing operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators.

The company intends to harvest the database of customers within its mortgage servicing operations as an essential source of additional growth, especially relative to the new alternative residential loan programs being offered.

Corporate Strengths

  • Experience – REZYFi is led by a seasoned management team with significant expertise spanning a wide range of real estate and financing subsectors. The team also has extensive experience in the cannabis and hemp marketplace, which the company intends to leverage as it navigates the changing landscape of the cannabis industry while sourcing the best opportunities in the sector.
  • Network of Independent Brokers – Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers. The company is currently training the network members on its new service offerings, with many already launching sales efforts. REZYFi believes this network will be a vital asset moving forward as other firms in the sector terminate relationships in the face of slowing mortgage business in a rising interest rate environment.
  • Proprietary Technology – REZYFi has invested heavily in designing, building and implementing proprietary automated/machine learning technology to shorten loan processing timeframes and increase efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below those of its competitors.

Market Overview

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals in the years to come.

In the first quarter of 2022, lenders issued 2.71 million residential loans, with the average balance for a first mortgage climbing to a record high of $298,324 in 2021, according to the Mortgage Bankers Association. This trend is expected to continue, with Freddie Mac forecasting a 10.4 percent increase in home prices in 2022 and a 5.0 percent bump in 2023. Growth prospects in the cannabis industry paint a similar picture.

The National Association of Realtors® issued a report in April 2021 examining the correlation between cannabis legalization and real estate demand. In states where prescription and recreational cannabis use is legal, more than a third of surveyed agents reported an increase in demand for warehouses. Likewise, 23 percent of those surveyed reported an increase in demand for storefronts, and 28 percent observed increased demand for land. As other states look to join the 19 that have embraced full cannabis legalization, this rising demand could create an opportunity for REZYFi’s cannabis-focused initiatives.

In total, an analysis by market research firm Business Research Insights projects the global loan servicing market to reach a value of nearly $1.5 billion by 2028, up from $680.8 million in 2021. Those figures represent a CAGR of 11.0 percent during the forecast period of 2022-2028.

Management Team

John Vu, Esq., is CEO of REZYFi, Inc. He has more than two decades of experience in the mortgage and commercial banking industry. He has filled many senior and executive management positions in high-producing mortgage banks, including C-level assignments. He has also served as general counsel for a nationally associated commercial bank. Mr. Vu brings considerable cannabis industry expertise to REZYFi. He has served as a corporate attorney to multiple cannabis cultivators, manufacturers and retailers.

Ji Ji Zhang, Esq., is CFO of REZYFi, Inc. He is a multifaceted entrepreneur who owns a law firm, a portfolio of hotels and a high-producing mortgage bank. Mr. Zhang is also an investor in the development of a cannabis business park. He brings more than five years of experience in mortgage banking to REZYFi, having developed Freddie Mac and HUD licenses and amassed a managed portfolio valued at over $300 million.

Kevin Heckemeyer is President of REZYFi, Inc. He has more than 25 years of experience in mortgage banking. He has built and sold several high producing mortgage businesses. In his current roles with ResMac, he is responsible for production and operations.

Spencer Dang is Chief Credit Officer of REZYFi, Inc. He has more than a decade of experience in mortgage operations. He is a direct endorsement underwriter for HUD and has specialized in non-QM underwriting. Under his watch as an underwriter, he has never had a single repurchase.

Recent News


Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Researchers have been busy, publishing more than 4,300 scientific papers on marijuana, making 2022’s tally a new record for annual cannabisresearch published. It is said that cannabis and its components arethe most understudied, yet they have attracted plenty ofresearchers’ attention in current times. With cannabis being afederally illicit substance, studying it would be most agreeable tomost people, especially given that more states are legalizingmarijuana in one form or another. Largely, a societal misconceptionhas it that cannabis is not extensively studied hence a lot ofmyths carry the day as far as policy reforms are concerned. Ananalysis targeting the federal site shows that more than4,300 scientific research publications have been made availableworldwide targeting cannabis and its derivatives. This number ofarticles exceeds last year’s 4,200 articles. As more research findsits way into the public domain, perceptions are likely to undergo adramatic shift, and it may not be long before many people take upthe legal cultivation of cannabis indoors using the latest compactindoor grow equipment from manufacturers such as Advanced Container Technologies Inc. (OTC: ACTX).

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Friday's trading session at $0.4, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2005/$1.42.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

BiondVax Pharmaceuticals was recently featured in a research reportby Zacks Small-Cap Research

The report highlighted BiondVax’s recent achievements, the mostnotable of which is the proof-of-concept animal trial thatdelivered positive results suggesting that the company’santi-COVID-19 NanoAb candidate resulted in milder and shorterillness

The company also received support and advice from the Paul EhrlichInstitute (“PEI”), which are viewed as key toward approval for aPhase 1/2a first-in-human clinical trial

The report estimates that BiondVax is fully funded for the next 12months; subsequent to the report’s publication, BiondVax raised anadditional $7.3 million net in an underwritten public offering

Accounting for a ratio change in the company’s ADS and based on aprobability-adjusted discounted cash flow (“DCF”) model, Zacksvalued the company at $57.00 per share

Calendar year 2022 has been eventful for BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, andcommercializing innovative immunotherapeutic products primarily forthe treatment of infectious diseases and autoimmune diseases.Recently, the company was covered in a recent research report byZacks Small-Cap Research ( The report valued the company at $57.00 per American depositaryshare (“ADS”) against a share price of $9.87 (as of December 8) andhighlighted BiondVax’s recent key milestones, starting with highlystatistically significant positive results from a preclinicalin-vivo proof-of-concept study of its inhaled anti-COVID-19nanosized antibodies (“NanoAbs”).


BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing andcommercializing innovative immunotherapeutic products primarily forthe treatment of infectious and autoimmune diseases, is reportingadditional results from a preclinical in vivo proof-of-conceptstudy. The study evaluated BVXV’s innovative inhaled nanosizedantibody (“NanoAb”) COVID-19 therapy; results indicate that thepresence of the SARS-COV-2 virus in the lungs of hamsters treatedwith BiondVax’s NanoAb was “virtually eliminated” and significantlyless than the amount of virus detected in the placebo group.Specifically, hamsters infected with SARS-COV-2 that were treatedwith BiondVax’s inhaled anti-COVID-19 nanosized antibodies had morethan 30 times lower lung viral titer on average compared to thosetreated with inhaled placebo. This information follow dataindicating that NanoAb treatment resulted in significantly milderillness and faster recovery in comparison to the placebo group.According to the announcement, BiondVax is formulating its NanoAbsas a self‑administered inhaled drug for treatment and potentialprophylactic prevention of COVID-19, with the first in-human phase1/2a clinical trial slated for this year. “We are thrilled with theresults of this ongoing trial,” said BiondVax CEO Amir Reichman inthe press release. “This study is not only a proof-of-concept forthe inhaled COVID-19 NanoAb, but also lights the way to developmentof a larger NanoAb pipeline. The current omicron outbreak in Chinahas demonstrated that continuous development of innovative and safetherapeutics for COVID-19 is the more effective and economical wayto contain this disease. Having a self-administered inhaledtherapeutic for those already infected that may also be used asprophylactic prevention for those at risk will address currentunmet needs, potentially bring massive relief to global publichealth, and save millions of lives going forward. I’m proud of theBiondVax team who are scaling-up in-house manufacturing of theNanoAbs and are already beginning to prepare for the next NanoAbsas therapies for other underserved medical conditions such aspsoriasis and asthma.” To view the full press release, visit

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Friday's trading session at $3, off by 5.1833%, on 4,710,606 volume. The average volume for the last 3 months is 4.711M and the stock's 52-week low/high is $2.80/$22.90.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton (NASDAQ: CPTN), a Silicon Valley innovator of high-performance lidar solutions, was featured in a recent article published by FreightWaves. The piece, written by Jack Daleo and titled “Cepton unveilsslimmed-down lidar solution,” discusses the Vista-X120 Plus, whichoffers easy integration at a height of 30 mm. “As the autonomousvehicle industry begins to gather steam, manufacturers of lidar —short for light detection and ranging — are trying to do more withless. Cepton (NASDAQ: CPTN), one of the few publicly traded lidarcompanies in the U.S., on Tuesday unveiled the Vista-X120 Plus,billed as ‘the world’s slimmest software definable, top-endautomotive lidar for real-time adaptive 3D perception.’ In otherwords, the system can be controlled or configured remotely viasoftware, is well-suited for cars and vans, and uses sensors toidentify obstacles both near and far,” the article reads. “But theVista-X120 Plus’ real differentiator is its size. With a height ofjust 30 millimeters, the hardware component of the system can beplaced on a vehicle during the OEM phase or at a later time withoutaffecting its appearance. And compared to Cepton’s Vista-X90 lidar,Vista-X120 Plus processes data at five times the rate and boasts afield of view that is 30 degrees wider — all while being half itsheight. Operators can also use software to alter the sensor’sregion of interest (‘ROI’) to as wide as 120 degrees and as high as25 degrees.”

To view the full article, visit

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Friday's trading session at $1.24, off by 0.8%, on 121,931 volume. The average volume for the last 3 months is 121,931 and the stock's 52-week low/high is $1.01/$80.16.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies (NASDAQ: FRGT), a technology company developing solutions to optimize andautomate the supply chain process and providing its Fr8App platformfor business-to-business, cross-border shipping in the USMCAregion, has announced its 2023 guidance for revenue. According tothe announcement, the company anticipates revenue this year toreach somewhere between $36 to $42 million; the company reported2022 revenue of approximately $26 to $27 million. “We look forwardto continued growth in our cross-border and domestic FTL offeringsover the course of the next 12 to 24 months and come into 2023 witha strong pipeline of existing customers and new prospects andgrowing lines of business,” said Fr8Tech CEO Javier Selgas in thepress release. “We are revising our guidance for 2023 revenues tobe in the $36 to $42 million range as we continue to invest in ourtechnology and are capturing early returns from our new productofferings. We are excited about our future prospects to continue todrive shareholder value.”

To view the full press release, visit

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.


Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Friday's trading session at $0.2342, off by 2.3353%, on 938,177 volume. The average volume for the last 3 months is 938,177 and the stock's 52-week low/high is $0.1799/$7.766.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.